Back to News
Feb 26, 2026 4:00 PM

Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths

Boston Scientific Corp (NYSE:BSX) on Wednesday initiated the removal of certain AXIOS Stents and Electrocautery-Enhanced Delivery Systems from clinical settings following reports of deployment complications that have been linked to serious injuries and deaths.

Stent Use

The AXIOS Electrocautery-Enhanced Stent and Delivery System is designed to enable endoscopic drainage of pancreatic pseudocysts or walled-off necrosis through transgastric or transduodenal access.

Certain models are also used to assist gallbladder drainage in high-risk surgical patients with acute cholecystitis, inflammation of the gallbladder.

Actions To Be Taken

According to the U.S. Food and Drug Administration (FDA), the company notified affected customers on December 19, 2025, advising them to stop ...